109 related articles for article (PubMed ID: 28396297)
1. The co-regulators SRC-1 and SMRT are involved in interleukin-6-induced androgen receptor activation.
Wang Q; Wang H; Ju Q; Ding Z; Ge X; Shi QM; Zhou JL; Zhou XL; Zhang JP; Zhang MR; Yu HM; Xu LC
Eur Cytokine Netw; 2016 Nov; 27(4):108-113. PubMed ID: 28396297
[TBL] [Abstract][Full Text] [Related]
2. Inhibition effect of cypermethrin mediated by co-regulators SRC-1 and SMRT in interleukin-6-induced androgen receptor activation.
Wang Q; Zhou JL; Wang H; Ju Q; Ding Z; Zhou XL; Ge X; Shi QM; Pan C; Zhang JP; Zhang MR; Yu HM; Xu LC
Chemosphere; 2016 Sep; 158():24-9. PubMed ID: 27239967
[TBL] [Abstract][Full Text] [Related]
3. Anti-androgenic mechanisms of Bisphenol A involve androgen receptor signaling pathway.
Wang H; Ding Z; Shi QM; Ge X; Wang HX; Li MX; Chen G; Wang Q; Ju Q; Zhang JP; Zhang MR; Xu LC
Toxicology; 2017 Jul; 387():10-16. PubMed ID: 28645579
[TBL] [Abstract][Full Text] [Related]
4. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
5. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
Yoon HG; Wong J
Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395
[TBL] [Abstract][Full Text] [Related]
6. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
8. Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression.
Godoy AS; Sotomayor PC; Villagran M; Yacoub R; Montecinos VP; McNerney EM; Moser M; Foster BA; Onate SA
Biochem Biophys Res Commun; 2012 Jul; 423(3):564-70. PubMed ID: 22695118
[TBL] [Abstract][Full Text] [Related]
9. Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells.
Buchanan G; Need EF; Barrett JM; Bianco-Miotto T; Thompson VC; Butler LM; Marshall VR; Tilley WD; Coetzee GA
Mol Cell Endocrinol; 2011 Aug; 342(1-2):20-31. PubMed ID: 21664238
[TBL] [Abstract][Full Text] [Related]
10. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells.
Ueda T; Mawji NR; Bruchovsky N; Sadar MD
J Biol Chem; 2002 Oct; 277(41):38087-94. PubMed ID: 12163482
[TBL] [Abstract][Full Text] [Related]
11. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
12. Anti-androgen effects of the pyrethroid pesticide cypermethrin on interactions of androgen receptor with corepressors.
Pan C; Wang Q; Liu YP; Xu LF; Li YF; Hu JX; Jiang M; Zhang JP; Zhang MR; Yu HM; Zhou JL; Zhou XL; Xu LC
Toxicology; 2013 Sep; 311(3):178-83. PubMed ID: 23831764
[TBL] [Abstract][Full Text] [Related]
13. Inability of NCoR/SMRT to repress androgen receptor transcriptional activity in prostate cancer cell lines.
Laschak M; Bechtel M; Spindler KD; Hessenauer A
Int J Mol Med; 2011 Oct; 28(4):645-51. PubMed ID: 21720703
[TBL] [Abstract][Full Text] [Related]
14. Binding of AR to SMRT/N-CoR complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB.
Trtkova K; Paskova L; Matijescukova N; Strnad M; Kolar Z
Neoplasma; 2010; 57(5):406-14. PubMed ID: 20568894
[TBL] [Abstract][Full Text] [Related]
15. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
Axlund SD; Lambert JR; Nordeen SK
Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
[TBL] [Abstract][Full Text] [Related]
16. The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor.
Kasina S; Macoska JA
Mol Cell Endocrinol; 2012 Apr; 351(2):249-63. PubMed ID: 22245379
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor signaling: mechanism of interleukin-6 inhibition.
Jia L; Choong CS; Ricciardelli C; Kim J; Tilley WD; Coetzee GA
Cancer Res; 2004 Apr; 64(7):2619-26. PubMed ID: 15059919
[TBL] [Abstract][Full Text] [Related]
18. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT.
Liao G; Chen LY; Zhang A; Godavarthy A; Xia F; Ghosh JC; Li H; Chen JD
J Biol Chem; 2003 Feb; 278(7):5052-61. PubMed ID: 12441355
[TBL] [Abstract][Full Text] [Related]
19. Effects of cypermethrin on the ligand-independent interaction between androgen receptor and steroid receptor coactivator-1.
Pan C; Liu YP; Li YF; Hu JX; Zhang JP; Wang HM; Li J; Xu LC
Toxicology; 2012 Sep; 299(2-3):160-4. PubMed ID: 22664485
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
